Reported a loss of $4.26 m for half year ending 31/12/03.This is...

Reported a loss of $4.26 m for half year ending 31/12/03.This is after fully expensing $5.04m R & D costs.Income for period $1.4m.Debt free with $16.6m cash in hand after exercising options and strong participation in share purchase plan.Current Phase 2b trials on obesity drug AOD9604 commenced 11/03 but results not expected until Q3/04.In summary--Financials look strong but had hoped for earlier results from trials.